BI-836858 |
BI-836858 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CART-33 (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia, Myeloid; Leukemia, Myeloid, Acute |
Details
|
Lintuzumab Ac-225 (Actinium Pharmaceuticals) |
225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 |
Phase 2 Clinical |
Pdl Biopharma Inc |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
VCAR-33 (Vor Biopharma) |
VCAR-33; VCAR33 |
Phase 2 Clinical |
Vor Biopharma Inc |
Leukemia, Myeloid, Acute |
Details
|
MP0533 |
MP0533 |
Phase 2 Clinical |
Molecular Partners Ag |
Leukemia, Myeloid, Acute |
Details
|
CD33 CAR T Cells(Beijing Boren Hospital) |
|
Phase 2 Clinical |
Beijing Gao Boren Hospital Co Ltd |
Leukemia; Neoplasms; Leukemia, Myeloid, Acute |
Details
|
Emerfetamab |
AMG-673; AMG673 |
Phase 1 Clinical |
Amgen Inc |
Leukemia, Myeloid, Acute |
Details
|
ICG-136 |
ICG-136; 123b-33bcCAR |
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Leukemia, Myeloid, Acute |
Details
|
Vixtimotamab |
T-564; AMV-564 |
Phase 1 Clinical |
Amphivena Therapeutics Inc |
Solid tumours; Myelodysplastic Syndromes |
Details
|
AL-003 |
AL-003 |
Phase 1 Clinical |
Abbvie Inc, Alector Inc |
Alzheimer Disease |
Details
|
PRGN-3006 |
PRGN-3006 |
Phase 1 Clinical |
Precigen Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
IM73 chimeric antigen receptor T cell therapy |
IM-73-CAR-T |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
ORM-6151 |
ORM-6151 |
Phase 1 Clinical |
Orum Therapeutics Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
SENTI-202 |
SENTI-202 |
Phase 1 Clinical |
Senti Biosciences Inc |
Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
JNJ-67571244 |
JNJ-67571244; JNJ-67371244; JNJ-1244 |
Phase 1 Clinical |
Johnson & Johnson |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CD33-NKE |
CD33-NKE; CD33 NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myeloid, Acute |
Details
|
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) |
|
Phase 1 Clinical |
Beijing GoBroad Hospital |
Leukemia, Myeloid, Acute |
Details
|
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) |
|
Phase 1 Clinical |
Shenzhen Geno-Immune Medical Institute |
Leukemia, Myeloid, Acute |
Details
|
CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd |
Neoplasm, Residual; Leukemia, Myeloid, Acute |
Details
|
CD33 CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd |
Neoplasm, Residual; Leukemia, Myeloid, Acute |
Details
|
IMGN-779 |
IMGN-779 |
Phase 1 Clinical |
Immunogen Inc |
Leukemia, Myeloid, Acute |
Details
|
Eluvixtamab |
MT-114; AMG-330 |
Phase 1 Clinical |
Amgen Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CLL-1/CD33 Targeted LCAR-AMDR Cells(Nanjing Legend Biotechnology) |
|
Phase 1 Clinical |
|
Leukemia, Myeloid, Acute |
Details
|
IBR-733 |
IBR-733; IBR733 |
Phase 1 Clinical |
Imbioray (Hangzhou) Biomedicine Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
CD33 CAR-T Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Leukemia, Myeloid, Acute |
Details
|
CLL1+CD33 CAR-T(Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Leukemia, Myeloid, Acute |
Details
|
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Hematologic Neoplasms; Leukemia, Myeloid, Acute |
Details
|
Anti-CD33/CLL1 CAR-NK Cell Therapy |
|
Phase 1 Clinical |
Imbioray (Hangzhou) Biomedicine Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
Lintuzumab Ac-225/Venetoclax |
|
Phase 1 Clinical |
Actinium Pharmaceuticals Inc |
Leukemia, Promyelocytic, Acute |
Details
|
DXC-007(Hangzhou Dac Biotech Company) |
DXC-007 |
Phase 1 Clinical |
Hangzhou Dac Biotech Company Ltd |
Leukemia; Leukemia, Myeloid, Acute |
Details
|
Lintuzumab-gelonin conjugate |
|
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
Anti-CD33/CLL-1 CAR-T (Legend) |
|
Phase 1 Clinical |
Legend Biotech Corp |
Leukemia, Promyelocytic, Acute |
Details
|
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) |
|
Phase 1 Clinical |
University Of California San Diego |
Leukemia, Myeloid, Acute |
Details
|
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
BI-836858 |
BI-836858 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CART-33 (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia, Myeloid; Leukemia, Myeloid, Acute |
Details
|
Lintuzumab Ac-225 (Actinium Pharmaceuticals) |
225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 |
Phase 2 Clinical |
Pdl Biopharma Inc |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
VCAR-33 (Vor Biopharma) |
VCAR-33; VCAR33 |
Phase 2 Clinical |
Vor Biopharma Inc |
Leukemia, Myeloid, Acute |
Details
|
MP0533 |
MP0533 |
Phase 2 Clinical |
Molecular Partners Ag |
Leukemia, Myeloid, Acute |
Details
|
CD33 CAR T Cells(Beijing Boren Hospital) |
|
Phase 2 Clinical |
Beijing Gao Boren Hospital Co Ltd |
Leukemia; Neoplasms; Leukemia, Myeloid, Acute |
Details
|
Emerfetamab |
AMG-673; AMG673 |
Phase 1 Clinical |
Amgen Inc |
Leukemia, Myeloid, Acute |
Details
|
ICG-136 |
ICG-136; 123b-33bcCAR |
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Leukemia, Myeloid, Acute |
Details
|
Vixtimotamab |
T-564; AMV-564 |
Phase 1 Clinical |
Amphivena Therapeutics Inc |
Solid tumours; Myelodysplastic Syndromes |
Details
|
AL-003 |
AL-003 |
Phase 1 Clinical |
Abbvie Inc, Alector Inc |
Alzheimer Disease |
Details
|
PRGN-3006 |
PRGN-3006 |
Phase 1 Clinical |
Precigen Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
IM73 chimeric antigen receptor T cell therapy |
IM-73-CAR-T |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
ORM-6151 |
ORM-6151 |
Phase 1 Clinical |
Orum Therapeutics Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
SENTI-202 |
SENTI-202 |
Phase 1 Clinical |
Senti Biosciences Inc |
Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
JNJ-67571244 |
JNJ-67571244; JNJ-67371244; JNJ-1244 |
Phase 1 Clinical |
Johnson & Johnson |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CD33-NKE |
CD33-NKE; CD33 NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myeloid, Acute |
Details
|
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) |
|
Phase 1 Clinical |
Beijing GoBroad Hospital |
Leukemia, Myeloid, Acute |
Details
|
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) |
|
Phase 1 Clinical |
Shenzhen Geno-Immune Medical Institute |
Leukemia, Myeloid, Acute |
Details
|
CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd |
Neoplasm, Residual; Leukemia, Myeloid, Acute |
Details
|
CD33 CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd |
Neoplasm, Residual; Leukemia, Myeloid, Acute |
Details
|
IMGN-779 |
IMGN-779 |
Phase 1 Clinical |
Immunogen Inc |
Leukemia, Myeloid, Acute |
Details
|
Eluvixtamab |
MT-114; AMG-330 |
Phase 1 Clinical |
Amgen Inc |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
CLL-1/CD33 Targeted LCAR-AMDR Cells(Nanjing Legend Biotechnology) |
|
Phase 1 Clinical |
|
Leukemia, Myeloid, Acute |
Details
|
IBR-733 |
IBR-733; IBR733 |
Phase 1 Clinical |
Imbioray (Hangzhou) Biomedicine Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
CD33 CAR-T Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Leukemia, Myeloid, Acute |
Details
|
CLL1+CD33 CAR-T(Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Leukemia, Myeloid, Acute |
Details
|
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Hematologic Neoplasms; Leukemia, Myeloid, Acute |
Details
|
Anti-CD33/CLL1 CAR-NK Cell Therapy |
|
Phase 1 Clinical |
Imbioray (Hangzhou) Biomedicine Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
Lintuzumab Ac-225/Venetoclax |
|
Phase 1 Clinical |
Actinium Pharmaceuticals Inc |
Leukemia, Promyelocytic, Acute |
Details
|
DXC-007(Hangzhou Dac Biotech Company) |
DXC-007 |
Phase 1 Clinical |
Hangzhou Dac Biotech Company Ltd |
Leukemia; Leukemia, Myeloid, Acute |
Details
|
Lintuzumab-gelonin conjugate |
|
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
Anti-CD33/CLL-1 CAR-T (Legend) |
|
Phase 1 Clinical |
Legend Biotech Corp |
Leukemia, Promyelocytic, Acute |
Details
|
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) |
|
Phase 1 Clinical |
University Of California San Diego |
Leukemia, Myeloid, Acute |
Details
|
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|